Abstract
Toxicokinetics has gained wide acceptance in validating dose related drug exposure in safety evaluation studies. Although exposure is confirmed by measuring blood levels, the concept of comparing safe/toxic blood concentrations in animals to those in man has not been fully realized. Furthermore, in many cases, the frequency of dosing in animal safety studies may not match with that proposed for use in man. Many examples exist demonstrating that the efficacy, safety and toxicity of a drug are influenced by the mode and frequency of drug administration. Although physiological differences between various animal species and man make direct extrapolations to man difficult, new techniques have been proposed which may allow for reasonably good estimates of pharmacokinetic parameters in man. A successful extrapolation would be very useful in planning and expediting early clinical trials. The relationship between safe dosages, pharmacologic-toxicologic activities, and blood levels can guide in selecting early dosages for initial administration to man and in subsequent dosing escalation strategy.
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bachmann, K. (1989). Predicting toxicokinetic parameters in humans from toxicokinetic data acquired from three small mammalian species. J. Appl. Toxicol.,9, 331–338.
Barry, H., and A. Yacobi (1984). Preclinical toxicokinetics. In A. Yacobi and H. Barry, III, (Eds.), Experimental and Clinical Toxicokinetics American Pharmaceutical Association, APS, Washington, DC, pp. 1–7.
Batra, V. K., and A. Yacobi (1989). An overview of toxicokinetics. In A. Yacobi, J. P. Skelly, and V. K. Batra (Eds.), Toxicokinetics and New Drug Development Pergamon Press, New York, NY, pp. 1–20.
Boxenbaum H. (1982). Interspecies scaling, allometry, physiological time, and the ground plan for pharmacokinetics. J. Pharmacokinet. Biopharm.,10, 201–227.
Boxenbaum, H. (1984). Interspecies pharmacokinetic scaling and the evolutionary-comparative paradigm. Drug Metab. Rev.,15, 1071–1121.
Boyd, E. M., and E. Crinsky (1970). The 100-day LD50 index of Captan. Acta Pharmacol. Toxicol.,29, 226–240.
Campbell, D. B., and R. M. J. Ings. (1988) New approaches to the use of pharmacokinetics in toxicology and drug development. Human Toxicol. 7, 469–479.
Chappell, W. R., and J. Mordenti (1991). Extrapolation of toxicological and pharmacological data from animals to humans. In B. Testa (Ed.), Advances in Drug Research Academic Press, London. pp. 1–116.
de la Iglesia, F. A., and P. Greaves (1989). Role of toxicokinetics in drug safety evaluations. In A. Yacobi, J. P. Skelly, and V. K. Batra (Eds.), Toxicokinetics and New Drug Development Pergamon Press, New York. pp. 21–32.
Doherty, P. A., V. H. Fern, and R. P. Smith (1982). Congenital malformations induced by infusion of cyanide in the golden hamster. Toxicol. Appl. Pharmacol.,64, 456–464.
Fisher, J. W., T. A. Whittaker, D. H. Taylor, H. J. Clewell III, and M. E. Andersen (1989). Physiologically based pharmacokinetic modeling of the pregnant rat: a multiroute exposure model for trichloroethylene and its metabolite, trichloroacetic acid. Toxicol. Appl. Pharmacol.,99, 395–414.
Gabrielsson, J. L. (1991). Utilization of physiologically based models in extrapolating pharmacokinetic data among species. Fund. Appl. Toxicol.,16, 230–232.
Gabrielsson, J. L., and K. S. Larsson (1987). The use of physiological pharmacokinetic models in studies on the disposition of salicylic acid in pregnancy. In H. Nau and W. J. Scott (Eds.), Pharmacokinetics in Teratogenesis CRC Press, Boca Raton, Florida. pp. 13–26.
Gaspari, F. and M. Bonati (1990). Interspecies metabolism and pharmacokinetic scaling of theophylline disposition. Drug Metab. Rev.,22, 179–207.
Glocklin, V. C., and C. C. Chah (1989). Toxicokinetics in preclinical evaluation of drug safety. In A. Yacobi, J. P. Skelly and V. K. Batra, (Eds.), Toxicokinetics and New Drug Development. Pergamon Press, New York, NY, pp. 33–41.
Hawkins, D. R., and L. F. Chasseaud (1985). Reasons for monitoring kinetics in safety evaluation studies. Arch. Toxicol. Suppl.,8, 165–172.
Hottendorf, G. H., D. R. VanHarken, H. Madissoo, and B. E. Cabana (1976). Pharmacokinetic considerations in toxicology. Proc. Eur. Soc. Toxicol.,17, 255–262.
Ings, R. M. J. (1990). Interspecies scaling and comparisons in drug development and toxicokinetics. Xenobiotica 20, 1201–1231.
Komuro, M., H. Matsushita, T. Maeda, T. Shindo, and Y. Kawaguchi (1990). Pharmacokinetic considerations of YP-14. ISSX, San Diego.
Levy, G. (1989). Some pharmacodynamic aspects of toxicokinetics. In A. Yacobi, J. P. Skelly, and V. K. Batra (Eds.), Toxicokinetics and New Drug Development Pergamon Press, New York. pp. 97–107.
Matsushita, H., H. Suzuki, Y. Sugiyama, Y. Sawada, T. Iga, M. Hanano, and Y. Kawaguchi (1990). Prediction of the pharmacokinetics of Cefodizime and Cefotetan in humans from pharmacokinetic parameters in animals. J. Pharmacobio. Dyn..13, 602–611.
Mordenti, J. (1985). Pharmacokinetic scale-up: accurate prediction of human pharmacokinetic profile from animal data. J. Pharm. Sci.,74, 1097–1099.
Mordenti, J. (1986). Man versus beast: pharmacokinetic scaling in mammals. J. Pharm. Sci., 75, 1028–1040.
Mordenti, J., and W. Chappell (1989). The use of interspecies scaling in toxicokinetics. In A. Yacobi, J. P. Skelly and V. K. Batra, (Eds.), Toxicokinetics and New Drug Development Pergamon Press, New York. pp. 42–96.
Nau, H. (1983). The role of delivery systems in toxicology and drug development. Pharm. Internat.,4, 228–231.
Nau, H. (1991). Pharmacokinetic considerations in the design and interpretation of developmental toxicity studies. Fund. Appl. Toxicol.,16, 219–221.
Patel, B.A., F. D. Boudinot, R. F. Schinazi, J. M. Gallo, and C. K. Chu (1990). Comparative pharmacokinetics and interspecies scaling of 3’-azido- 3’deoxythymidine (AZT) in several mammalian species. J. Pharmacobio. Dyn.,13, 206–211.
Paustenback, D. J., H. J. Clewell, III, M. L. Gargas, and M. E. Andersen (1988). Physiologically based pharmacokinetic model for inhaled carbon tetrachloride. Toxicol. Appl. Pharmacol.,96, 191–211.
Powell, S. H., W. L. Thompson, M. A. Luthe, R. C. Stern, D. A. Grossniklaus, D. D. Bloxham, D. L. Groden, M. R. Jacobs, A. O. DiScenna, H. A. Cash, and J. D. Klinger (1983). Once daily vs. continuous aminoglycoside dosing: efficacy and toxicity in animal and clinical studies of gentamicin, nethilmicin and tobramycin. J. Infect. Dis., 147 918–932.
Reitz, R. H., J. N. McDougal, M. W. Himmelstein, R. J. Nolan, and A. M. Shumann (1988). Physiologically based pharmacokinetic modeling with methylchloroform: implications for interspecies, high dose/low dose and dose route extrapolations. Toxicol. Appl. Pharmacol.,95, 185–199.
Sacher, G. A. (1959). Relation of lifespan to brain weight and body weight in mammals. In G. E. W. Wolstenholme, and M. O’Connor (Eds.), Ciba Foundation Colloquia on Aging. Vol. 5., Churchill, London, pp. 115–133.
US FDA, Division of Antiviral Drug Products (1989). Reference guide for the nonclinical toxicity studies of antiviral drugs indicated for the treatment of non-life threatening diseases: evaluation of drug toxicity prior to Phase I clinical studies.
Voisin, E. M., M. Ruthsatz, J. M. Collins, and P. C. Hoyle (1990). Extrapolation of animal toxicity to humans: interspecies comparisons in drug development. Regul. Toxicol. Pharmacol.,12, 107–116.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1993 Springer Science+Business Media New York
About this chapter
Cite this chapter
Leal, M., Yacobi, A., Batra, V.K. (1993). Use of Toxicokinetic Principles in Drug Development: Bridging Preclinical and Clinical Studies. In: Yacobi, A., Skelly, J.P., Shah, V.P., Benet, L.Z. (eds) Integration of Pharmacokinetics, Pharmacodynamics, and Toxicokinetics in Rational Drug Development. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-1520-0_8
Download citation
DOI: https://doi.org/10.1007/978-1-4757-1520-0_8
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4757-1522-4
Online ISBN: 978-1-4757-1520-0
eBook Packages: Springer Book Archive